Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Assets (2016 - 2025)

Sangamo Therapeutics (SGMO) has 16 years of Assets data on record, last reported at $88.6 million in Q3 2025.

  • For Q3 2025, Assets fell 20.33% year-over-year to $88.6 million; the TTM value through Sep 2025 reached $88.6 million, down 20.33%, while the annual FY2024 figure was $101.6 million, 38.52% down from the prior year.
  • Assets reached $88.6 million in Q3 2025 per SGMO's latest filing, down from $97.6 million in the prior quarter.
  • Across five years, Assets topped out at $877.1 million in Q1 2021 and bottomed at $86.2 million in Q1 2025.
  • Average Assets over 5 years is $394.3 million, with a median of $325.1 million recorded in 2023.
  • Peak YoY movement for Assets: surged 50.12% in 2021, then tumbled 71.39% in 2024.
  • A 5-year view of Assets shows it stood at $721.9 million in 2021, then dropped by 22.08% to $562.5 million in 2022, then crashed by 70.61% to $165.3 million in 2023, then plummeted by 38.52% to $101.6 million in 2024, then fell by 12.78% to $88.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Assets were $88.6 million in Q3 2025, $97.6 million in Q2 2025, and $86.2 million in Q1 2025.